This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

In patients with extensive-stage small cell lung cancer (ES-SCLC), tarlatamab, a bispecific T-cell engager, plus durvalumab as first-line maintenance therapy extended median overall survival by more than eight months, more than tripled progression-free survival and reduced the risk of death by 58% compared to durvalumab alone, according to results of the phase 3 open-label, multicenter, randomized DeLLphi-305 study.

The results were presented by Jacob Sands, M.D., associate chief of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute, during the Presidential Symposium at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain, on Oct. 24. Overall survival benefits were consistent across subgroups, including patients with brain and liver metastases.

The interim phase 3 results were simultaneously published in the New England Journal of Medicine.

"This trial is positive in every way. We have seen substantial improvement in median progression-free survival, substantial improvement in median overall survival, and we're improving the time of disease control substantially for a broader group of patients than what we've seen from any prior study and any prior treatment," says Sands. "This immunotherapy combination sets a new standard of care with tarlatamab plus durvalumab in the maintenance setting after induction chemotherapy plus durvalumab."

DeLLphi-305 is the first phase 3 study including a bispecific T-cell engager therapy to demonstrate an overall survival benefit in the first-line maintenance setting for ES-SCLC.

Source link